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Abstract
Introduction: Loss to follow-up is a major challenge in the prevention of mother to child transmission of HIV (PMTCT)
programme in Malawi with reported loss to follow-up of greater than 70%. Tingathe-PMTCT is a pilot intervention that utilizes
dedicated community health workers (CHWs) to create a complete continuum of care within the PMTCT cascade, improving
service utilization and retention of mothers and infants.We describe the impact of the intervention on longitudinal care starting
with diagnosis of the mother at antenatal care (ANC) through final diagnosis of the infant.
Methods: PMTCT service utilization, programme retention and outcomes were evaluated for pregnant women living with HIV
and their exposed infants enrolled in the Tingathe-PMTCT programme between March 2009 and March 2011. Multivariate
logistic regression was done to evaluate maternal factors associated with failure to complete the cascade.
Results: Over 24 months, 1688 pregnant women living with HIV were enrolled. Median maternal age was 27 years (IQR, 23.8 to
30.8); 333 (19.7%) were already on ART. Among the remaining women, 1328/1355 (98%) received a CD4 test, with 1243/1328
(93.6%) receiving results. Of the 499 eligible for ART, 363 (72.8%) were successfully initiated. Prior to, delivery there were
93 (5.7%) maternal/foetal deaths, 137 (8.1%) women transferred/moved, 51 (3.0%) were lost and 58 (3.4%) refused ongoing
PMTCT services. Of the 1318 live births to date, 1264 (95.9%) of the mothers and 1285 (97.5%) of the infants received ARV
prophylaxis; 1064 (80.7%) infants were tested for HIV by PCR and started on cotrimoxazole. Median age at PCR was 1.7 months
(IQR, 1.5 to 2.5). Overall transmission at first PCR was 43/1047 (4.1%). Of the 43 infants with positive PCR results, 36 (83.7%)
were enrolled in ART clinic and 33 (76.7%) were initiated on ART.
Conclusions: Case management and support by dedicated CHWs can create a continuum of longitudinal care in the PMTCT
cascade and result in improved outcomes.
Keywords: prevention of mother to child transmission (PMTCT); early infant diagnosis (EID); paediatric HIV; HIV; task shifting;
community engagement; community health workers; retention; loss to follow up.
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Introduction
In 2011, UNAIDS announced a call to eliminate new
paediatric HIV infections among children by 2015 [1].
Effective medical interventions for prevention of mother to
child transmission of HIV (PMTCT) have been known since
the late 1990s, and in developed countries, almost no new
paediatric HIV infections occur [2,3]. Globally, though, an
estimated 370,000 children acquired HIV in 2009, the vast
majority through vertical transmission [1]. This disparity in
outcomes has not been due to a lack of effective medications
or tools. The World Health Organization (WHO) PMTCT
guidelines detail simple and effective interventions that
make transmission rates of less than 5% feasible, even
among breastfeeding populations [4]. Rather, persistent
poor outcomes in developing countries are the result of
mothers living with HIV and exposed infants not receiving the
full array of available services [58].
Figure 1 provides details on the full PMTCT cascade and
current utilization rates in sub-Saharan Africa. National
guidelines and programs in high burden countries, including
Malawi, often subdivide aspects of this cascade into separate
PMTCT (vertical transmission), antiretroviral therapy (ART),
early infant diagnosis (EID) and paediatric HIV programs,
frequently with different providers and service locations for
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each component. Resulting poor utilization of available
services, lack of coordination between providers and high
rates of loss to follow-up have led to persistent high infection
rates in exposed children [1,8,9]. It has been shown that,
even with highly efficacious combination antiretroviral
interventions, only marginal reductions in childhood HIV
infections can be achieved without improved retention of
pregnant mothers and infants within the PMTCT cascade of
services [10]. Human resource shortages in high burden
countries further compound programme inefficiencies and
limit the ability of the healthcare system to make improve-
ments. If the goal of eliminating new paediatric infections is
to be reached, interventions to improve health systems
performance and to address human resource needs are
required. Task shifting with the use of community health
workers (CHWs) has been suggested as one strategy to
Figure 1. The PMTCT cascade of services: steps, estimates of coverage in sub-Saharan Africa and CHW responsibilities in the programme.
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address these challenges within resource-limited settings
[1115].
In March 2009, Baylor College of Medicine Children’s
Foundation Malawi, in collaboration with the Malawi Ministry
of Health (MOH), initiated a pilot community-based interven-
tion in Lilongwe that uses lay CHWs as a bridge linking the
government PMTCT, EID and paediatric HIV programs. Called
Tingathe-PMTCT (meaning ‘‘yes we can’’ in the local Chichewa
language), the intervention was designed to create a new
paradigm in PMTCT service delivery and end the compart-
mentalization of services into distinct PMTCT, EID and
paediatric HIV subunits [9]. Tingathe CHWs ensured long-
itudinal care throughout the full PMTCTcascade, starting with
diagnosis of the mother at antenatal care (ANC) and ending
with final diagnosis and treatment of the infant. This paper
provides details on the pilot intervention as well as a current
snapshot of our patient cohort. Impact on patient retention,
utilization of services and outcomes was evaluated.
Methods
Intervention setting and patient population
The Tingathe-PMTCT pilot programme took place in Area 25
and Kawale, two large peri-urban communities in Lilongwe.
The estimated population is 310,000 people, with 15,000
Figure 2. (a) Components of the PMTCT cascade available at programme intervention sites. (b) Curriculum of community health worker
training.
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deliveries/year, 2000 HIV-exposed infants delivered/year and
12% adult HIV prevalence [16]. Over 96% of pregnant women
attend at least one antenatal visit [17] and 99% of ANC
attendees are tested for HIV [18,19].
Routine PMTCT services available at intervention sites
All PMTCT clinical care was provided in accordance with MOH
and WHO guidelines [20,21]. Figure 2a details all components
of the PMTCT cascade available at the intervention sites.
HIV testing, counselling and consent were conducted via opt-
out testing per MOH guidelines.
At the start of our programme, ART eligibility was defined
as WHO Stage 3 or 4 or CD45250 cells/mm3 [21]. ART
eligibility changed in August 2010 to CD45350 cells/mm3 for
pregnant or lactating women living with HIV.
For women who did not qualify for ART, single dose
nevirapine for the mother and infant and a bottle of
zidovudine (AZT) syrup for the infant was dispensed at the
first ANC visit. AZT was dispensed beginning at 28 weeks, and
mothers returned for monthly refills. A 1-week supply of AZT/
lamivudine (3TC) tail was distributed during labour and
delivery [21].
During the intervention period, the national infant feeding
guidelines recommended exclusive breastfeeding until 6
months of age followed by gradual weaning [22,23]. Universal
ART initiation for HIV-infected infants younger than 1 year of
age was the standard of care.
Preintervention data
We used three sources for preintervention data. The first was
a published report of maternal and infant utilization of
PMTCT, EID and paediatric HIV services at five sites (including
our two intervention sites) within Lilongwe between 2004
and 2008 [19]. This source contained preintervention com-
parison data for PMTCT prophylaxis, infant PCRs and ART
initiation for HIV-infected infants. For information not
included in this report, we used the 2004 Malawi Demo-
graphic and Health Survey, which provided national statistics
for numbers of women accessing ANC, location of delivery
and infant feeding choice after birth [17]. Finally, ANC CD4
log records documented CD4 test dates and whether or
not results were returned to pregnant women. Consistent
records were not kept at A25. At Kawale, records were
available from March to October 2008.
Details of the pilot intervention
Intervention overview
The main focus of this programme was CHW-based patient
case management in both the health facility and community
(Figure 1). The intervention began at ANC when pregnant
women identified as living with HIV were assigned a
dedicated CHW and voluntarily enrolled into the programme.
CHWs ensured that mother-infant pairs received all necessary
PMTCT services. They followed their clients at their homes
and at health centres, from initial diagnosis up until con-
firmation of definitive HIV-uninfected status after cessation
of breastfeeding or successful ART initiation for HIV-infected
infants. Receipt of PMTCT was recorded only upon confirma-
tion with the mother after delivery to verify that medication
had actually been ingested, not just dispensed [7]. Women
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Figure 3. Steps of PMTCT cascade completed by mother-infant pairs in programme intervention.
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or after the birth of the infant were also followed up and
provided services but were not included in this cohort.
CHW selection, training and roles
Criterion for CHW selection included living within the
community, completion of primary schooling and ability to
read and write in English and Chichewa, ability to ride a
bicycle and HIV-infected or affected. Both men and women
were recruited. Due to the large volume of applicants, we
first conducted group interviews, inviting those who per-
formed well in these for individual interviews. Once selected,
CHWs earned a stipend for work-related transportation and
food (2.50 USD/day).
A specialized 2-week training, followed by a 2-week on-site
orientation, was developed (Figure 2b). Trainees were moni-
tored closely by supervisors and were only allowed to conduct
unsupervised patient visits after competency had been
verified. CHWs also received half-day quarterly refresher
trainings by Baylor paediatricians.
To help free up clinical staff for essential clinical care,
specific tasks were shifted to CHWs, including patient
registration, nutritional assessments, infant feeding counsel-
ling, pill counting and distribution of nutritional supplements.
All CHWs were responsible for both health centre-based tasks
(40% time) and community work (60% time). CHWs generally
followed up to a maximum of 50 mother-infant pairs at one
time.
Community sensitization/education
Prior to the programme intervention, consultative meetings
were conducted with community leaders. CHWs conducted
daily education sessions in the health centres and held
ongoing sensitization meetings in the community. The main
focus of education was promoting the utilization of PMTCT,
EID and paediatric HIV treatment services.
Monitoring, evaluating and supervising CHW activities
An individual patient mastercard was used to facilitate
patient case management, and a patient register was used
to monitor CHW activities. The mother-infant mastercard was
opened on programme entry, updated after every visit and
key data entered into registers weekly. Information from
registers was entered into a Microsoft Access database
bimonthly. CHWs were supervised weekly by site supervisors
and monthly by the programme coordinator. Supervisors also
conducted unscheduled visits with patients to ensure that
they were satisfied with the services being provided. CHWs
received bi-annual performance evaluations.
Programme exit/patient outcomes
Mother-infant pairs exited the programme if they reached one
of the following outcomes: (1) maternal death; (2) miscar-
riage, stillbirth; (3) infant death; (4) transferred/moved out-
side the catchment area; (5) lost (patient tracing attempted
but patient could not be found); (6) despite counselling,
patient refused to return for clinical care; (7) infant infected
and successfully enrolled into care and started on ART; and
(8) infant definitively not infected (weaned and repeat PCR
negative).
Statistical analysis
Data from pregnant women and exposed infants enrolled in
the Tingathe-PMTCT programme between March 2009 and
March 2011 were analysed. The closing date for follow-up
was October 31, 2011. Data were de-identified prior to
analysis. Aggregate data were reported as mean with
standard deviation or median with interquartile range (IQR)
based on normality. For the multivariate logistic regres-
sion, all outcomes preventing completion of the PMTCT
cascade were grouped together including miscarriage/foetal
demise, maternal/infant death, transferred/moved, lost and
refused ongoing care. To identify factors that predicted non-
completion, unadjusted and adjusted odds ratios and 95%
confidence intervals were obtained using binary and multi-
variate logistic regression, respectively. All covariates, irre-
spective of the significance of the binary model, were
entered into the multivariate model by forward stepwise
selection, with entry testing based on the significance of the
score statistic and removal testing based on the likelihood-
ratio statistic with conditional parameter estimates. Only
covariates with a significant score statistic (pB0.05) were
retained in the final model. Analyses were performed using
IBM SPSS Statistics (version 19; SPSS, Inc., Chicago, IL, USA).
The Malawi National Health Sciences Research Committee
and the Baylor College of Medicine institutional review board
granted ethics approval.
Results
Maternal characteristics at enrolment
Records from 1688 pregnant women living with HIV were
analysed (Table 1). The majority, 92.9%, enrolled during their
second or third trimesters and 76.3% were newly diagnosed
with HIV. At enrolment, 19.7% were on ART.
Service utilization of antenatal components
of the PMTCT cascade
CHWs tracked service utilization by each mother-infant
pair through the PMTCT cascade (Table 2, Figure 3). Of those
mothers not on ART at enrolment, 98% had a CD4 drawn, and
93.6% of these mothers received these results. This compares
to 22.5% who received results before the intervention.
Based on CD4 count, 36.8% of mothers met criteria for
ART eligibility. Of these, 72.8% were successfully initiated on
ART.
Of the 1318 live births, 87.3% received the most ideal
combination of either full combination prophylaxis (47.3%) or
ART (40%). Prior to the intervention, only 8.8% of mothers
received ART.
Prior to delivery, there were 5.7% maternal/foetal deaths/
still births, 8.1% transferred/moved. 3.0% lost and 3.4%
refused ongoing PMTCT services. There were 1.8% women
still recorded as pregnant as of the closing date for data
analysis.
Service utilization of postnatal components
of the PMTCT cascade
Of the 1318 live births, 97.5% received infant PMTCT, and
90.5% received the correct single dose nevirapine plus AZT
tail (see Table 2 and Figure 3).
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DNA PCR testing was performed on 80.7% of the infants.
Of the remaining infants, 3.2% were still awaiting their
first PCR, and 16.1% exited the programme (as a result of
being lost, died, transferred, moved and refused ongoing
care) before first PCR. The median age at first PCR was 1.7
months (IQR, 1.5 to 2.5). The overall MTCT transmission rate
was 4.1%.
Of the 43 infants found to be HIV-infected, 76.7% were
started on ART, with median age at initiation of 4.9 months
(IQR, 4.0 to 6.0). This is in contrast to the preintervention
period where 34.4% on infected infants were started on ART
at a median age of 9.1 months (IQR, 5.4 to 13.8).
Outcomes and continued follow up
Overall, of the initial 1688 women, 1% of mothers died, 4.9%
of pregnancies terminated in miscarriages and stillbirths and
3.7% infants died. Furthermore, 16.8% mother-infant pairs
moved out of the catchment area, 5.0% were lost, 10.8%
refused ongoing care and 16.5% exited the programme
after receiving a definitive HIV-negative diagnosis. Of those
182 mothers who refused care, 31.8% refused care during
pregnancy, 45.6% refused after delivery but before first
PCR and 22.5% refused after the first PCR. There are 672
mother-infant pairs still active in the programme, including
31 mothers who are still pregnant and 641 exposed infants
still being breastfed.
Maternal characteristics at programme enrolment
associated with failure to complete PMTCT cascade
In bivariate analysis, maternal age of at least 20 years, along
with being ART-eligible but not on ART, were associated with
failure to complete the PMTCT cascade, whereas enrolment
later in pregnancy and having a partner who was not
involved (partner dead or separated from mother) were
associated with a higher rate of successful completion of the
cascade (Table 3). On multivariate analyses, two variables
predicted failure to complete the PMTCT cascade, namely,
being ART-eligible but not receiving therapy (odds ratio (OR),
1.69; 95% confidence interval (CI), 1.18 to 2.42) and having a
partner who was involved but not disclosed to (unaware of
the maternal HIV status; OR, 1.54; 95% CI, 1.06 to 2.23). On
the other hand, the strongest predictors of successful
completion of the PMTCT cascade were enrolment in the
third trimester (OR, 0.37; 95% CI, 0.24 to 0.58), having newly
diagnosed HIV infection (OR, 0.50; 95% CI, 0.33 to 0.75) and
having a partner who was not involved (OR, 0.43; 95% CI,
0.24 to 0.78).
Discussion
Ensuring a continuum of care between services in the PMTCT
cascade is essential if the goal of ending new paediatric HIV
infection is to be reached. Our results demonstrate that
coordinated, longitudinal care of mother-infant pairs is
possible in high-burden, resource-limited countries like
Malawi. In this intervention, dedicated CHWs functioning as
case coordinators created a bridge between disparate clinical
services and improved retention and service utilization at
virtually every step within the PMTCT cascade.
Key areas of improvement for mothers included receiving
CD4 counts, being started appropriately on ART if eligible and
receiving proper combination prophylaxis if not eligible for
ART. Prior to our intervention, over 90% of women only
received single dose nevirapine, reflecting the slow adoption
of the 2006 WHO recommendations [20,21]. In our cohort,
the majority of mother-infant pairs received the recom-
mended regimen of either combination prophylaxis or ART,
resulting in a significant reduction in HIV transmission at first
PCR. Enrolment of exposed infants into care, measurement
and receipt of DNA PCR results and, finally, initiation of ART
for infected infants also improved dramatically.
Our results show marked improvement in retention
compared, not only to preintervention data from Malawi
Table 1. Characteristics of mothers at programme enrolment
Total (n1688)
Median maternal age, years (IQR) 27.0 (23.8 to 30.8)
Trimester of pregnancy, n (%)
First (0 to 13 weeks) 107 (6.3)
Second (14 to 26) 1025 (60.7)
Third (27 to 40) 543 (32.2)
Unknown-missing 13 (0.8)
HIV status at enrolment, n (%)
Already known to be HIV-infected 400 (23.7)
Newly diagnosed as HIV-infected 1288 (76.3)
ART eligibility by CD4 counta, n (%)
On ART 333 (19.7)
ART eligible 499 (29.6)
Does not meet ART criterion 777 (46)
ART eligibility was not determined 79 (4.7)
WHO stage at programme registration, n (%)
Stage 1/2 30 (1.7)
Stage 3 11 (0.7)
Stage 4 8 (0.5)
Not done 1639 (97.1)
CD4 cells/mm3 for women not on ARTb 1355
B200, n (%) 204 (15.1)
200 to 349, n (%) 336 (24.8)
350 to 499, n (%) 353 (26.0)
]500, n (%) 375 (27.7)
CD4 taken but unknown resultc 60 (4.4)
CD4 not taken 27 (2.0)
Partner disclosure status, n (%)d
Partner involved and disclosed 423 (25.1)
Partner involved but not disclosed 1158 (68.6)
Partner not involved 106 (6.3)
Missing data 1 (B0.0)
aDefinition of ART eligibility changed in August 2010 from CD45250
cells/mm3 to CD45350 cells/mm3 for HIV-infected pregnant
women; bCD4 routinely performed only on women not already on
ART at registration; cthe majority of these were CD4 samples that
were clotted or otherwise could not be processed by the laboratory
facility; dpartner disclosed defined as partner having knowledge of
maternal HIV status. Partner non-involved defined as a partner who
is dead or is otherwise separated from the mother.
Abbreviations: IQR, interquartile range; ART, antiretroviral therapy.
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Table 2. Steps of the PMTCT cascade completed by mother-infant pairs: preintervention data and programme intervention results




ACCESS Antenatal Care Pregnant women accessing antenatal care 96.4% [Ref. 17]a NA
TEST for HIV infection and
ENROLL into care
Number of women tested for HIV 99% [Ref. 19]b NA
HIV-infected pregnant women, n 1688
DETERMINE ART eligibility ART status, n/N (%)
on ART Unknown 333/1688 (19.7)
Not on ART Unknown 1355/1688 (80.3)
Needed CD4 testing 1355
Mom received CD4 testing, n/N (%) 91.3%b,c 1328/1355 (98)
CD4 results returned to health centre from
laboratory, n/N (%)
Unknown 1268/1328 (95.5)
Mom received CD4 results, n/N (%) 22.5%b,c 1243/1328 (93.6)
INITIATE ART/PMTCT
prophylaxis
ART eligible by CD4 count, n/N (%)d 499/1688 (29.6)
Started on ART, n/N (%) Unknown 363/499 (72.8)
Number of live births to date, n 1318
Mom received PMTCT prophylaxis or ART n/N (%) 1264/1318 (95.9)
Nevirapine only 90.6% [Ref. 19]b (meds
distributed at ANC only)
39/1318 (2.9)
Nevirapine and AZT only Not applicablee 75/1318 (5.7)
Full combination prophylaxis (sdNVP, AZT and
Combivir)
Not applicablee 624/1318 (47.3)
Antiretroviral therapy for mothers health 8.8% [Ref. 19]b 526/1318 (40.0)
None 0.1% 53/1318 (4.0)
Unknown/missing data Not applicable 1/1318 (0.1)
FOLLOW UP Place of delivery, n/N (%)
Hospital/health centre 57.2% [Ref. 17]a 1273/1318 (96.6)
Home 29.4% [Ref. 17]a 36/1318 (2.7)
Traditional birth attendant 12.1% [Ref. 17]a 2/1318 (0.2)
Other/unknown/missing data 1.2% [Ref. 17]a 7/1318 (0.5)
POSTNATAL
ACCESS Postnatal Care Infant received PMTCT prophylaxis, n/N (%) 1285/1318 (97.5)
Nevirapine only 47.2% [Ref. 19]b 89/1318 (6.8)
Neviparine and zidovudine Not applicablee 1193/1318 (90.5)
AZT syrup only Not applicablee 3/1318 (0.2)
None Not applicable 22/1318 (1.7)
Unknown/missing data 52.8% [Ref. 19]b 11/1318 (0.8)
Infant feeding choice after birth, n/N (%)
Exclusive breastfeeding 75.2% [Ref. 17]a 1249/1318 (94.8)
Replacement feeding 1.6% [Ref. 17]a 20/1318 (1.5)
Mixed feeding 23.3% [Ref. 17]a 2/1318 (0.2)
Unknown/missing data 47/1318 (3.5)
TEST for HIV infection and
ENROLL into care
Infant received PCR test and CPT, n/N (%)f 53.6% [Ref. 19]b 1064/1318 (80.7)
Number (%) tested at 52months of age Unknown 680/1064 (63.9)
Number (%) tested at 53months of age Unknown 904/1064 (85)
Median infant age at first HIV DNA PCR, months
(IQR)
3 (0.5 to 8.6) [Ref. 19]b 1.7 (1.5 to 2.5)
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but also to reports from other countries within the region.
WHO estimates that in sub-Saharan Africa, only half of
women living with HIV receive any PMTCT intervention,
43% of HIV-exposed infants receive ARV prophylaxis and a
mere 6% to 15% of HIV-exposed infants receive an HIV test
[24,25].
The small percentage of infants receiving HIV testing is an
especially important issue [26]. Improving the continuum of
care within the PMTCT cascade is not only critical for
preventing HIV in exposed infants but also for reducing
mortality in those infants who become infected. The CHER
study demonstrated that HIV-infected infants suffer from
rapid immunologic deterioration, disease progression and
high mortality without early ART initiation [27]. By linking
mothers to infants, our CHWs were able to significantly
improve DNA PCR testing and entry into care and
thereby improve the rate of prompt ART initiation in infected
infants.
CHW case management improved not only programme
implementation but monitoring as well. Several studies have
documented that data collected and reported within national
PMTCT programmes are often inaccurate and incomplete
[28,29]. Some have suggested routine HIV testing of infants
at immunization clinics and inpatient facilities as a means for
improving PMTCT monitoring [30]. While such testing is
important and will provide reliable measures for programme
evaluation, the opportunities for effective interventions have
largely been missed by the time testing takes place. CHW
case management, by contrast, facilitates both service
delivery and programme monitoring.
Though our results demonstrate a marked improvement
over preintervention data, we have not yet achieved the
desired goal of greater than 90% delivery at each step of the
cascade for PMTCT to be optimally effective [10]. Reasons for
attrition included refusal to continue follow-up, movement
from the area and loss to follow up, such that close to a third
of the cohort did not complete the programme.
The population we serve is highly mobile, as demonstrated
by the 16.8% of patients who moved outside the catchment
area. Many mothers within our programme returned to their
home villages for additional support. Though our CHWs were
often aware of the move and were able to keep in touch with
some of their clients, for most, they had no means to
document whether or not mothers successfully entered care
in their new location. A national medical ID system would
assist with this type of tracking [19]. Within the programme,
we are developing improved predelivery counselling to
identify those mothers planning to return to home villages,
exploring strategies with maternal support groups organized
by home villages, and cell-phone text messaging to track
clients if they move outside our direct service areas.
We are conducting qualitative studies to further evaluate
reasons for and possible strategies to mitigate refusal of CHW
follow-up. Refusals occur throughout the cascade. Couples
counselling and testing with enhanced disclosure support
may help reduce refusal during pregnancy. Characterizing and
addressing misconceptions about testing results and the
likelihood of infection may reduce the number of mothers
refusing to get their children tested. Stressing the importance
of follow-up testing after weaning may reduce the number of
patients who default after a negative first PCR. Malawi’s
increasing emphasis on family-centred HIV care may also
encourage partners to attend clinic together, possibly
improving communication and retention in care [31].
Male involvement has been touted as a possible way to
engage more women in PMTCTservices. Our findings (Table 3)
Table 2 (Continued )





First DNA PCR test result returned from lab 53.6% [Ref. 19]b 1047/1064 (98.2)
First DNA PCR test results given to the caregiver Unknown 1024/1064 (96.2)
Median time from first DNA PCR test to results
given to caregiver, days (IQR)
Unknown 47.5 (29.0 to 63.0)
First DNA PCR result negative 86.2% 1004/1047 (95.9)
First DNA PCR result positive 13.8% [Ref. 19]b 43/1047 (4.1)
INITIATE ART Enrolled in ART clinic 29.5% [Ref. 19]b 36/43 (83.7)
Infected children started on ART 34.4% [Ref. 19]b 33/43 (76.7)
Median age at ART initiation months (IQR) 9.1 (5.4 to 13.8) [Ref. 19]b 4.9 (4.0 to 6.0)
FOLLOW UP Mother-infant pairs still being followed in
programme intervention
672
aMalawi countrywide data; bpreintervention data from intervention sites; cdata from Kawale site CD4 logbooks, March to October 2008;
ddefinition of ART eligibility changed in August 2010 from CD45250 cells/mm3 to CD45350 cells/mm3 for HIV-infected pregnant women; eonly
maternal ART and nevirapine for mother and infant were available during the preintervention period; fof the 1318 live births, 212 were
discharged from the programme due to death, moving to another location or refusing ongoing care prior to receiving their first PCR; 42 infants
are still active in the programme and awaiting their first PCR.
Abbreviations: ART, antiretroviral therapy; sd-NVP, single dose nevirapine; AZT, zidovudine; PCR, polymerase chain reaction; CPT, cotrimoxazole
prophylaxis, IQR, interquartile range.
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suggest that women without any partner involvement were
most likely to complete the cascade, whereas those women
with involved but undisclosed partners were least likely. These
findings not only reemphasize the importance of partner
disclosure but also highlight the potentially obstructive role
that partners may play in accessing services, as observed in
other studies [32], or the value of women’s independence to
make their own decisions.
There are several limitations to our study. The first is a lack
of directly comparable preintervention data. Our prior
referenced study was from the same area and immediately
preceded our intervention, retrospectively analysing all
available records over a 4-year period [19]. By contrast, the
present study only followed up patients enrolled in the
Tingathe programme, which may have introduced measure-
ment bias and favourably skewed outcomes. On the other
hand, the prior study had a much longer follow-up period
and also included infant testing data from the inpatient ward
at Kamuzu Central Hospital and the attached Baylor Centre of
Excellence, which may have inflated the infant follow-up
results. Many of these infants likely fell out of the PMTCT
cascade, but reentered when ill and were identified on
admission at Kamuzu Central Hospital or the Baylor Centre of
Excellence. Despite these qualifications, this report provided
the most direct preintervention data with which to compare
our results. Moving forward, the data presented here
provides a good baseline for similarly designed prospective
programmatic studies.
Our second limitation was that we did not measure ANC
attendance or HIV testing at ANC. As prior studies had
already demonstrated both were over 95% [1719] in our
setting, we did not independently assess this. This limits the
external validity of our study, as ANC attendance and HIV
testing rates are not as robust in many comparable settings.
Third, we noted that some women were lost between HIV
testing and referral to our CHWs. To address this issue, HIV
testing at ANC was largely shifted to our CHWs, so that
registration could be made immediately upon diagnosis. We
do not have good data on how many women may have
refused services between HIV testing and enrolment into our
programme. To address this issue, we have developed an
enrolment register that we are now piloting at our sites. This,
combined with improved documentation of testing within
ANC, will provide us with solid data on this critical service
point in the future [31].
Finally, this programme was not implemented as part of a
controlled trial, and there were other providers of services at
various time points during the intervention. These providers
may also have contributed to the overall improved outcomes
observed.
Changes being made in the Malawi PMTCT guidelines
provide both new opportunities and challenges for effective
Table 3. Maternal characteristics at programme enrolment associated with failure to complete PMTCT cascadea
n/N (%) (n1688) OR of failure (95% CI) p-value AOR of failure (95% CI)b p-value
Maternal age, n (%)
Maternal ageB20 35/110 (31.8) 1.00
20 673/1578 (42.6) 1.59 (1.05 to 2.41) 0.027  0.056
Trimester of pregnancy, n (%)
First 58/107 (54.2) 1.00 1.00
Second 480/1025 (46.8) 0.74 (0.50 to 1.11) 0.147 0.79 (0.52 to 1.19) 0.260
Third 164/543 (30.2) 0.37 (0.24 to 0.56) B0.001 0.37 (0.24 to 0.58) B0.001
Missing data 13
HIV status at enrolment, n (%)
Already known to be HIV-infected 178/400 (44.5) 1.00 1.00
Newly diagnosed as HIV-infected 530/1288 (41.1) 0.87 (0.70 to 1.09) 0.236 0.50 (0.33 to 0.75) B0.001
ART eligibility at enrolment, n (%)
On ART 134/333 (40.2) 1.00 1.00
Eligible but not on ART 244/499 (48.9) 1.42 (1.07 to 1.88) 0.014 1.69 (1.18 to 2.42) 0.004
Not eligible 284/777 (36.6) 0.86 (0.66 to 1.11) 0.245 1.09 (0.77 to 1.54) 0.632
Missing data 79
Partner disclosure status at enrolment, n (%)c
Partner involved and disclosed 177/423 (41.8) 1.00 1.00
Partner involved, not disclosed 510/1158 (44.0) 1.09 (0.87 to 1.37) 0.435 1.54 (1.06 to 2.23) 0.024
Partner not involved 21/106 (19.8) 0.34 (0.12 to 0.58) B0.001 0.43 (0.24 to 0.78) 0.005
Missing 1
aFailure to complete PMTCT cascade defined as maternal death, miscarriage, abortion, infant death, transferred out, moved, lost or refusal of
ongoing care prior to the infant’s final HIV-negative diagnosis or if found to be HIV-infected-initiatied on ART; ball five covariates were tested for
entry into the multivariate model, and all covariates except maternal age were retained in the final equation, based on the significance (p-value)
of the Wald score; cpartner disclosed defined as partner having knowledge of maternal HIV status. Partner non-involved defined as a partner
who has died or is otherwise separated from the mother.
Abbreviations: OR, odds ratio; CI, confidence interval; ART, antiretroviral therapy.
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service delivery. In 2011, Malawi adopted an approach for
PMTCT referred to as Option B, where pregnant and
lactating women living with HIV will automatically be started
on ART for life [33]. This welcome approach simplifies the
maternal assessment, obviating the need for CD4 measure-
ments. However, the efficacy of this simplified approach will
be compromised unless efforts are made to link newly
identified women to ART services and to ensure identifica-
tion, enrolment into care and testing of exposed infants. This
is especially true as infant feeding guidelines now recom-
mend breastfeeding for all children, including HIV-exposed
infants, through the second year of life [31]. Furthermore, we
need to ensure that pregnant women present earlier to care,
as a significant portion of women in our study presented late.
We also need to prevent women from refusing care and
dropping out, for whatever reason. Ensuring continued
clinical care and follow-up testing after weaning through
this extended period will be a considerable challenge that
may be facilitated by CHW case management.
Conclusions
We believe the Tingathe-PMTCT programme has defined a
new paradigm for PMTCT service delivery. We attempted to
break down the compartmentalization and resulting loss to
follow-up between PMTCT, EID and paediatric HIV services.
We believe that with further refinement, CHWs can help
establish a system in which mothers and infants are
effectively followed up and linked throughout the full PMTCT
cascade. Establishing such systems that ensure continuity of
care will be critical if the goal of ending new paediatric
infections is to be reached.
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